nodes	percent_of_prediction	percent_of_DWPC	metapath
Cabergoline—HTR7—vein—ovarian cancer	0.0217	0.126	CbGeAlD
Cabergoline—HTR2A—vein—ovarian cancer	0.0136	0.0784	CbGeAlD
Cabergoline—DRD4—testis—ovarian cancer	0.0064	0.037	CbGeAlD
Cabergoline—ADRA1D—epithelium—ovarian cancer	0.00564	0.0326	CbGeAlD
Cabergoline—DRD5—female reproductive system—ovarian cancer	0.00523	0.0302	CbGeAlD
Cabergoline—HTR2B—myometrium—ovarian cancer	0.005	0.0289	CbGeAlD
Cabergoline—DRD5—female gonad—ovarian cancer	0.00476	0.0275	CbGeAlD
Cabergoline—ADRA1D—female reproductive system—ovarian cancer	0.00419	0.0242	CbGeAlD
Cabergoline—ADRA2C—myometrium—ovarian cancer	0.00393	0.0227	CbGeAlD
Cabergoline—HTR2B—uterine cervix—ovarian cancer	0.00389	0.0225	CbGeAlD
Cabergoline—HTR2B—decidua—ovarian cancer	0.00371	0.0214	CbGeAlD
Cabergoline—HTR2B—endometrium—ovarian cancer	0.00352	0.0203	CbGeAlD
Cabergoline—HTR7—epithelium—ovarian cancer	0.00336	0.0194	CbGeAlD
Cabergoline—HTR2B—uterus—ovarian cancer	0.00324	0.0187	CbGeAlD
Cabergoline—ADRA1A—epithelium—ovarian cancer	0.00324	0.0187	CbGeAlD
Cabergoline—HTR1B—female reproductive system—ovarian cancer	0.00324	0.0187	CbGeAlD
Cabergoline—ADRA2A—myometrium—ovarian cancer	0.00314	0.0181	CbGeAlD
Cabergoline—HTR1D—female reproductive system—ovarian cancer	0.00313	0.0181	CbGeAlD
Cabergoline—HTR2C—female reproductive system—ovarian cancer	0.0031	0.0179	CbGeAlD
Cabergoline—ADRA2C—uterine cervix—ovarian cancer	0.00306	0.0177	CbGeAlD
Cabergoline—ADRB1—female reproductive system—ovarian cancer	0.00304	0.0176	CbGeAlD
Cabergoline—ADRA2C—decidua—ovarian cancer	0.00292	0.0169	CbGeAlD
Cabergoline—HTR2B—female reproductive system—ovarian cancer	0.00291	0.0168	CbGeAlD
Cabergoline—HTR7—gonad—ovarian cancer	0.00279	0.0162	CbGeAlD
Cabergoline—ADRA2C—endometrium—ovarian cancer	0.00277	0.016	CbGeAlD
Cabergoline—HTR2B—vagina—ovarian cancer	0.00264	0.0152	CbGeAlD
Cabergoline—HTR2A—embryo—ovarian cancer	0.00257	0.0148	CbGeAlD
Cabergoline—ADRA2C—uterus—ovarian cancer	0.00255	0.0147	CbGeAlD
Cabergoline—HTR7—female reproductive system—ovarian cancer	0.0025	0.0144	CbGeAlD
Cabergoline—ADRA2A—uterine cervix—ovarian cancer	0.00244	0.0141	CbGeAlD
Cabergoline—ADRA2A—decidua—ovarian cancer	0.00233	0.0135	CbGeAlD
Cabergoline—ADRA2A—endometrium—ovarian cancer	0.00221	0.0128	CbGeAlD
Cabergoline—HTR2A—epithelium—ovarian cancer	0.00209	0.0121	CbGeAlD
Cabergoline—ADRA2C—female gonad—ovarian cancer	0.00209	0.0121	CbGeAlD
Cabergoline—ADRA2C—vagina—ovarian cancer	0.00207	0.012	CbGeAlD
Cabergoline—ADRA2A—gonad—ovarian cancer	0.00205	0.0118	CbGeAlD
Cabergoline—ADRA2A—uterus—ovarian cancer	0.00204	0.0118	CbGeAlD
Cabergoline—HTR7—testis—ovarian cancer	0.00201	0.0116	CbGeAlD
Cabergoline—DRD2—testis—ovarian cancer	0.0019	0.011	CbGeAlD
Cabergoline—ADRA2C—testis—ovarian cancer	0.00185	0.0107	CbGeAlD
Cabergoline—ADRA2A—female reproductive system—ovarian cancer	0.00183	0.0106	CbGeAlD
Cabergoline—HTR2A—gonad—ovarian cancer	0.00174	0.0101	CbGeAlD
Cabergoline—HTR2B—lymph node—ovarian cancer	0.0017	0.00985	CbGeAlD
Cabergoline—ADRA2A—female gonad—ovarian cancer	0.00167	0.00963	CbGeAlD
Cabergoline—ADRA2A—vagina—ovarian cancer	0.00166	0.00957	CbGeAlD
Cabergoline—HTR2A—female reproductive system—ovarian cancer	0.00156	0.009	CbGeAlD
Cabergoline—ADRA2A—testis—ovarian cancer	0.00148	0.00854	CbGeAlD
Cabergoline—CYP3A4—female reproductive system—ovarian cancer	0.00144	0.00833	CbGeAlD
Cabergoline—HTR2A—vagina—ovarian cancer	0.00141	0.00814	CbGeAlD
Cabergoline—Asthenia—Melphalan—ovarian cancer	0.00138	0.00178	CcSEcCtD
Cabergoline—Gastrointestinal pain—Vinorelbine—ovarian cancer	0.00137	0.00178	CcSEcCtD
Cabergoline—Flatulence—Paclitaxel—ovarian cancer	0.00136	0.00176	CcSEcCtD
Cabergoline—Pruritus—Melphalan—ovarian cancer	0.00136	0.00176	CcSEcCtD
Cabergoline—Tension—Paclitaxel—ovarian cancer	0.00136	0.00176	CcSEcCtD
Cabergoline—Rhinitis—Docetaxel—ovarian cancer	0.00135	0.00175	CcSEcCtD
Cabergoline—Cardiac failure—Epirubicin—ovarian cancer	0.00134	0.00174	CcSEcCtD
Cabergoline—Nervousness—Paclitaxel—ovarian cancer	0.00134	0.00174	CcSEcCtD
Cabergoline—ADRA2C—lymph node—ovarian cancer	0.00134	0.00776	CbGeAlD
Cabergoline—Diarrhoea—Topotecan—ovarian cancer	0.00134	0.00174	CcSEcCtD
Cabergoline—Back pain—Paclitaxel—ovarian cancer	0.00134	0.00173	CcSEcCtD
Cabergoline—Muscle spasms—Paclitaxel—ovarian cancer	0.00133	0.00172	CcSEcCtD
Cabergoline—Abdominal pain—Vinorelbine—ovarian cancer	0.00133	0.00172	CcSEcCtD
Cabergoline—Oedema peripheral—Docetaxel—ovarian cancer	0.00133	0.00172	CcSEcCtD
Cabergoline—Diarrhoea—Melphalan—ovarian cancer	0.00131	0.0017	CcSEcCtD
Cabergoline—Osteoarthritis—Epirubicin—ovarian cancer	0.00131	0.0017	CcSEcCtD
Cabergoline—Nausea—Chlorambucil—ovarian cancer	0.00131	0.00169	CcSEcCtD
Cabergoline—Hot flush—Doxorubicin—ovarian cancer	0.0013	0.00168	CcSEcCtD
Cabergoline—Visual impairment—Docetaxel—ovarian cancer	0.0013	0.00168	CcSEcCtD
Cabergoline—Dizziness—Topotecan—ovarian cancer	0.0013	0.00168	CcSEcCtD
Cabergoline—Menopausal symptoms—Doxorubicin—ovarian cancer	0.00129	0.00167	CcSEcCtD
Cabergoline—Ill-defined disorder—Paclitaxel—ovarian cancer	0.00128	0.00166	CcSEcCtD
Cabergoline—Face oedema—Epirubicin—ovarian cancer	0.00127	0.00164	CcSEcCtD
Cabergoline—HTR2A—testis—ovarian cancer	0.00126	0.00726	CbGeAlD
Cabergoline—Cardiac disorder—Docetaxel—ovarian cancer	0.00125	0.00162	CcSEcCtD
Cabergoline—Vomiting—Topotecan—ovarian cancer	0.00125	0.00161	CcSEcCtD
Cabergoline—Malaise—Paclitaxel—ovarian cancer	0.00125	0.00161	CcSEcCtD
Cabergoline—Cardiac failure—Doxorubicin—ovarian cancer	0.00124	0.00161	CcSEcCtD
Cabergoline—Vertigo—Paclitaxel—ovarian cancer	0.00124	0.00161	CcSEcCtD
Cabergoline—Syncope—Paclitaxel—ovarian cancer	0.00124	0.0016	CcSEcCtD
Cabergoline—Rash—Topotecan—ovarian cancer	0.00124	0.0016	CcSEcCtD
Cabergoline—Hypersensitivity—Vinorelbine—ovarian cancer	0.00124	0.0016	CcSEcCtD
Cabergoline—Dermatitis—Topotecan—ovarian cancer	0.00123	0.0016	CcSEcCtD
Cabergoline—Blood creatinine increased—Epirubicin—ovarian cancer	0.00123	0.00159	CcSEcCtD
Cabergoline—Headache—Topotecan—ovarian cancer	0.00123	0.00159	CcSEcCtD
Cabergoline—Palpitations—Paclitaxel—ovarian cancer	0.00122	0.00158	CcSEcCtD
Cabergoline—Vomiting—Melphalan—ovarian cancer	0.00122	0.00158	CcSEcCtD
Cabergoline—Loss of consciousness—Paclitaxel—ovarian cancer	0.00121	0.00157	CcSEcCtD
Cabergoline—Osteoarthritis—Doxorubicin—ovarian cancer	0.00121	0.00157	CcSEcCtD
Cabergoline—Liver function test abnormal—Epirubicin—ovarian cancer	0.00121	0.00157	CcSEcCtD
Cabergoline—Rash—Melphalan—ovarian cancer	0.00121	0.00157	CcSEcCtD
Cabergoline—Dermatitis—Melphalan—ovarian cancer	0.00121	0.00157	CcSEcCtD
Cabergoline—Asthenia—Vinorelbine—ovarian cancer	0.0012	0.00156	CcSEcCtD
Cabergoline—Arrhythmia—Docetaxel—ovarian cancer	0.0012	0.00156	CcSEcCtD
Cabergoline—Abdominal pain upper—Epirubicin—ovarian cancer	0.0012	0.00155	CcSEcCtD
Cabergoline—Orthostatic hypotension—Epirubicin—ovarian cancer	0.0012	0.00155	CcSEcCtD
Cabergoline—Hypertension—Paclitaxel—ovarian cancer	0.00119	0.00154	CcSEcCtD
Cabergoline—Alopecia—Docetaxel—ovarian cancer	0.00119	0.00154	CcSEcCtD
Cabergoline—Pruritus—Vinorelbine—ovarian cancer	0.00119	0.00154	CcSEcCtD
Cabergoline—Arthralgia—Paclitaxel—ovarian cancer	0.00118	0.00152	CcSEcCtD
Cabergoline—Anxiety—Paclitaxel—ovarian cancer	0.00117	0.00152	CcSEcCtD
Cabergoline—Face oedema—Doxorubicin—ovarian cancer	0.00117	0.00152	CcSEcCtD
Cabergoline—Nausea—Topotecan—ovarian cancer	0.00116	0.00151	CcSEcCtD
Cabergoline—Discomfort—Paclitaxel—ovarian cancer	0.00116	0.00151	CcSEcCtD
Cabergoline—Gastritis—Epirubicin—ovarian cancer	0.00116	0.0015	CcSEcCtD
Cabergoline—Dry mouth—Paclitaxel—ovarian cancer	0.00115	0.00149	CcSEcCtD
Cabergoline—Diarrhoea—Vinorelbine—ovarian cancer	0.00115	0.00149	CcSEcCtD
Cabergoline—Nausea—Melphalan—ovarian cancer	0.00114	0.00148	CcSEcCtD
Cabergoline—Confusional state—Paclitaxel—ovarian cancer	0.00114	0.00147	CcSEcCtD
Cabergoline—Blood creatinine increased—Doxorubicin—ovarian cancer	0.00114	0.00147	CcSEcCtD
Cabergoline—Influenza—Epirubicin—ovarian cancer	0.00113	0.00147	CcSEcCtD
Cabergoline—Back pain—Docetaxel—ovarian cancer	0.00113	0.00147	CcSEcCtD
Cabergoline—Oedema—Paclitaxel—ovarian cancer	0.00113	0.00146	CcSEcCtD
Cabergoline—Muscle spasms—Docetaxel—ovarian cancer	0.00113	0.00146	CcSEcCtD
Cabergoline—Liver function test abnormal—Doxorubicin—ovarian cancer	0.00112	0.00145	CcSEcCtD
Cabergoline—Shock—Paclitaxel—ovarian cancer	0.00111	0.00144	CcSEcCtD
Cabergoline—Dizziness—Vinorelbine—ovarian cancer	0.00111	0.00144	CcSEcCtD
Cabergoline—Orthostatic hypotension—Doxorubicin—ovarian cancer	0.00111	0.00144	CcSEcCtD
Cabergoline—Abdominal pain upper—Doxorubicin—ovarian cancer	0.00111	0.00144	CcSEcCtD
Cabergoline—Bronchitis—Epirubicin—ovarian cancer	0.00109	0.00141	CcSEcCtD
Cabergoline—Hyperhidrosis—Paclitaxel—ovarian cancer	0.00109	0.00141	CcSEcCtD
Cabergoline—Anorexia—Paclitaxel—ovarian cancer	0.00108	0.00139	CcSEcCtD
Cabergoline—Gastritis—Doxorubicin—ovarian cancer	0.00107	0.00139	CcSEcCtD
Cabergoline—ADRA2A—lymph node—ovarian cancer	0.00107	0.00619	CbGeAlD
Cabergoline—Vomiting—Vinorelbine—ovarian cancer	0.00107	0.00138	CcSEcCtD
Cabergoline—Rash—Vinorelbine—ovarian cancer	0.00106	0.00137	CcSEcCtD
Cabergoline—Dermatitis—Vinorelbine—ovarian cancer	0.00106	0.00137	CcSEcCtD
Cabergoline—Hypotension—Paclitaxel—ovarian cancer	0.00105	0.00136	CcSEcCtD
Cabergoline—Upper respiratory tract infection—Epirubicin—ovarian cancer	0.00105	0.00136	CcSEcCtD
Cabergoline—Headache—Vinorelbine—ovarian cancer	0.00105	0.00136	CcSEcCtD
Cabergoline—Syncope—Docetaxel—ovarian cancer	0.00105	0.00136	CcSEcCtD
Cabergoline—Influenza—Doxorubicin—ovarian cancer	0.00105	0.00136	CcSEcCtD
Cabergoline—Palpitations—Docetaxel—ovarian cancer	0.00104	0.00134	CcSEcCtD
Cabergoline—Weight increased—Epirubicin—ovarian cancer	0.00103	0.00134	CcSEcCtD
Cabergoline—Loss of consciousness—Docetaxel—ovarian cancer	0.00103	0.00133	CcSEcCtD
Cabergoline—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	0.00103	0.00133	CcSEcCtD
Cabergoline—Weight decreased—Epirubicin—ovarian cancer	0.00103	0.00133	CcSEcCtD
Cabergoline—Insomnia—Paclitaxel—ovarian cancer	0.00102	0.00132	CcSEcCtD
Cabergoline—Pneumonia—Epirubicin—ovarian cancer	0.00102	0.00132	CcSEcCtD
Cabergoline—Paraesthesia—Paclitaxel—ovarian cancer	0.00101	0.00131	CcSEcCtD
Cabergoline—Hypertension—Docetaxel—ovarian cancer	0.00101	0.00131	CcSEcCtD
Cabergoline—Bronchitis—Doxorubicin—ovarian cancer	0.00101	0.00131	CcSEcCtD
Cabergoline—Dyspnoea—Paclitaxel—ovarian cancer	0.00101	0.0013	CcSEcCtD
Cabergoline—Somnolence—Paclitaxel—ovarian cancer	0.001	0.0013	CcSEcCtD
Cabergoline—Arthralgia—Docetaxel—ovarian cancer	0.000997	0.00129	CcSEcCtD
Cabergoline—Nausea—Vinorelbine—ovarian cancer	0.000996	0.00129	CcSEcCtD
Cabergoline—Dyspepsia—Paclitaxel—ovarian cancer	0.000993	0.00129	CcSEcCtD
Cabergoline—Urinary tract infection—Epirubicin—ovarian cancer	0.000983	0.00127	CcSEcCtD
Cabergoline—Decreased appetite—Paclitaxel—ovarian cancer	0.00098	0.00127	CcSEcCtD
Cabergoline—Dry mouth—Docetaxel—ovarian cancer	0.000975	0.00126	CcSEcCtD
Cabergoline—Upper respiratory tract infection—Doxorubicin—ovarian cancer	0.000975	0.00126	CcSEcCtD
Cabergoline—Fatigue—Paclitaxel—ovarian cancer	0.000972	0.00126	CcSEcCtD
Cabergoline—Constipation—Paclitaxel—ovarian cancer	0.000965	0.00125	CcSEcCtD
Cabergoline—Pain—Paclitaxel—ovarian cancer	0.000965	0.00125	CcSEcCtD
Cabergoline—Confusional state—Docetaxel—ovarian cancer	0.000964	0.00125	CcSEcCtD
Cabergoline—Oedema—Docetaxel—ovarian cancer	0.000956	0.00124	CcSEcCtD
Cabergoline—Weight increased—Doxorubicin—ovarian cancer	0.000955	0.00124	CcSEcCtD
Cabergoline—Epistaxis—Epirubicin—ovarian cancer	0.000954	0.00123	CcSEcCtD
Cabergoline—Weight decreased—Doxorubicin—ovarian cancer	0.000949	0.00123	CcSEcCtD
Cabergoline—Pneumonia—Doxorubicin—ovarian cancer	0.000941	0.00122	CcSEcCtD
Cabergoline—Shock—Docetaxel—ovarian cancer	0.000941	0.00122	CcSEcCtD
Cabergoline—Feeling abnormal—Paclitaxel—ovarian cancer	0.000929	0.0012	CcSEcCtD
Cabergoline—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.000922	0.00119	CcSEcCtD
Cabergoline—Anorexia—Docetaxel—ovarian cancer	0.000911	0.00118	CcSEcCtD
Cabergoline—Rhinitis—Epirubicin—ovarian cancer	0.00091	0.00118	CcSEcCtD
Cabergoline—Urinary tract infection—Doxorubicin—ovarian cancer	0.000909	0.00118	CcSEcCtD
Cabergoline—Oedema peripheral—Epirubicin—ovarian cancer	0.000894	0.00116	CcSEcCtD
Cabergoline—Hypotension—Docetaxel—ovarian cancer	0.000893	0.00116	CcSEcCtD
Cabergoline—Abdominal pain—Paclitaxel—ovarian cancer	0.000892	0.00115	CcSEcCtD
Cabergoline—Epistaxis—Doxorubicin—ovarian cancer	0.000882	0.00114	CcSEcCtD
Cabergoline—Visual impairment—Epirubicin—ovarian cancer	0.000875	0.00113	CcSEcCtD
Cabergoline—Musculoskeletal discomfort—Docetaxel—ovarian cancer	0.000871	0.00113	CcSEcCtD
Cabergoline—Insomnia—Docetaxel—ovarian cancer	0.000865	0.00112	CcSEcCtD
Cabergoline—Paraesthesia—Docetaxel—ovarian cancer	0.000858	0.00111	CcSEcCtD
Cabergoline—Dyspnoea—Docetaxel—ovarian cancer	0.000852	0.0011	CcSEcCtD
Cabergoline—Somnolence—Docetaxel—ovarian cancer	0.00085	0.0011	CcSEcCtD
Cabergoline—Cardiac disorder—Epirubicin—ovarian cancer	0.000842	0.00109	CcSEcCtD
Cabergoline—Rhinitis—Doxorubicin—ovarian cancer	0.000842	0.00109	CcSEcCtD
Cabergoline—Dyspepsia—Docetaxel—ovarian cancer	0.000842	0.00109	CcSEcCtD
Cabergoline—Decreased appetite—Docetaxel—ovarian cancer	0.000831	0.00108	CcSEcCtD
Cabergoline—Hypersensitivity—Paclitaxel—ovarian cancer	0.000831	0.00108	CcSEcCtD
Cabergoline—Oedema peripheral—Doxorubicin—ovarian cancer	0.000827	0.00107	CcSEcCtD
Cabergoline—Fatigue—Docetaxel—ovarian cancer	0.000824	0.00107	CcSEcCtD
Cabergoline—Pain—Docetaxel—ovarian cancer	0.000818	0.00106	CcSEcCtD
Cabergoline—Constipation—Docetaxel—ovarian cancer	0.000818	0.00106	CcSEcCtD
Cabergoline—Arrhythmia—Epirubicin—ovarian cancer	0.000811	0.00105	CcSEcCtD
Cabergoline—Visual impairment—Doxorubicin—ovarian cancer	0.000809	0.00105	CcSEcCtD
Cabergoline—Asthenia—Paclitaxel—ovarian cancer	0.000809	0.00105	CcSEcCtD
Cabergoline—Alopecia—Epirubicin—ovarian cancer	0.000802	0.00104	CcSEcCtD
Cabergoline—Pruritus—Paclitaxel—ovarian cancer	0.000798	0.00103	CcSEcCtD
Cabergoline—Feeling abnormal—Docetaxel—ovarian cancer	0.000788	0.00102	CcSEcCtD
Cabergoline—Gastrointestinal pain—Docetaxel—ovarian cancer	0.000782	0.00101	CcSEcCtD
Cabergoline—Cardiac disorder—Doxorubicin—ovarian cancer	0.000779	0.00101	CcSEcCtD
Cabergoline—Flatulence—Epirubicin—ovarian cancer	0.000779	0.00101	CcSEcCtD
Cabergoline—Tension—Epirubicin—ovarian cancer	0.000775	0.001	CcSEcCtD
Cabergoline—Diarrhoea—Paclitaxel—ovarian cancer	0.000772	0.000999	CcSEcCtD
Cabergoline—Nervousness—Epirubicin—ovarian cancer	0.000767	0.000994	CcSEcCtD
Cabergoline—Back pain—Epirubicin—ovarian cancer	0.000764	0.00099	CcSEcCtD
Cabergoline—Muscle spasms—Epirubicin—ovarian cancer	0.00076	0.000984	CcSEcCtD
Cabergoline—Abdominal pain—Docetaxel—ovarian cancer	0.000756	0.000979	CcSEcCtD
Cabergoline—Arrhythmia—Doxorubicin—ovarian cancer	0.00075	0.000971	CcSEcCtD
Cabergoline—Dizziness—Paclitaxel—ovarian cancer	0.000746	0.000966	CcSEcCtD
Cabergoline—Alopecia—Doxorubicin—ovarian cancer	0.000742	0.000961	CcSEcCtD
Cabergoline—Ill-defined disorder—Epirubicin—ovarian cancer	0.000733	0.000949	CcSEcCtD
Cabergoline—Flatulence—Doxorubicin—ovarian cancer	0.00072	0.000933	CcSEcCtD
Cabergoline—Tension—Doxorubicin—ovarian cancer	0.000717	0.000929	CcSEcCtD
Cabergoline—Vomiting—Paclitaxel—ovarian cancer	0.000717	0.000929	CcSEcCtD
Cabergoline—Malaise—Epirubicin—ovarian cancer	0.000712	0.000923	CcSEcCtD
Cabergoline—Rash—Paclitaxel—ovarian cancer	0.000711	0.000921	CcSEcCtD
Cabergoline—Dermatitis—Paclitaxel—ovarian cancer	0.00071	0.00092	CcSEcCtD
Cabergoline—Nervousness—Doxorubicin—ovarian cancer	0.00071	0.000919	CcSEcCtD
Cabergoline—Vertigo—Epirubicin—ovarian cancer	0.00071	0.000919	CcSEcCtD
Cabergoline—Syncope—Epirubicin—ovarian cancer	0.000709	0.000917	CcSEcCtD
Cabergoline—Back pain—Doxorubicin—ovarian cancer	0.000707	0.000916	CcSEcCtD
Cabergoline—Headache—Paclitaxel—ovarian cancer	0.000707	0.000915	CcSEcCtD
Cabergoline—Hypersensitivity—Docetaxel—ovarian cancer	0.000704	0.000912	CcSEcCtD
Cabergoline—Muscle spasms—Doxorubicin—ovarian cancer	0.000703	0.00091	CcSEcCtD
Cabergoline—Palpitations—Epirubicin—ovarian cancer	0.000698	0.000904	CcSEcCtD
Cabergoline—Loss of consciousness—Epirubicin—ovarian cancer	0.000694	0.000899	CcSEcCtD
Cabergoline—Asthenia—Docetaxel—ovarian cancer	0.000686	0.000888	CcSEcCtD
Cabergoline—Hypertension—Epirubicin—ovarian cancer	0.000682	0.000883	CcSEcCtD
Cabergoline—Ill-defined disorder—Doxorubicin—ovarian cancer	0.000678	0.000878	CcSEcCtD
Cabergoline—Pruritus—Docetaxel—ovarian cancer	0.000676	0.000876	CcSEcCtD
Cabergoline—Arthralgia—Epirubicin—ovarian cancer	0.000673	0.000871	CcSEcCtD
Cabergoline—Anxiety—Epirubicin—ovarian cancer	0.00067	0.000868	CcSEcCtD
Cabergoline—Nausea—Paclitaxel—ovarian cancer	0.00067	0.000867	CcSEcCtD
Cabergoline—Discomfort—Epirubicin—ovarian cancer	0.000665	0.000861	CcSEcCtD
Cabergoline—Malaise—Doxorubicin—ovarian cancer	0.000659	0.000854	CcSEcCtD
Cabergoline—Dry mouth—Epirubicin—ovarian cancer	0.000658	0.000852	CcSEcCtD
Cabergoline—Vertigo—Doxorubicin—ovarian cancer	0.000657	0.00085	CcSEcCtD
Cabergoline—Syncope—Doxorubicin—ovarian cancer	0.000656	0.000849	CcSEcCtD
Cabergoline—Diarrhoea—Docetaxel—ovarian cancer	0.000654	0.000847	CcSEcCtD
Cabergoline—Confusional state—Epirubicin—ovarian cancer	0.00065	0.000842	CcSEcCtD
Cabergoline—Palpitations—Doxorubicin—ovarian cancer	0.000646	0.000837	CcSEcCtD
Cabergoline—Oedema—Epirubicin—ovarian cancer	0.000645	0.000835	CcSEcCtD
Cabergoline—Loss of consciousness—Doxorubicin—ovarian cancer	0.000643	0.000832	CcSEcCtD
Cabergoline—Shock—Epirubicin—ovarian cancer	0.000634	0.000821	CcSEcCtD
Cabergoline—Dizziness—Docetaxel—ovarian cancer	0.000632	0.000819	CcSEcCtD
Cabergoline—Hypertension—Doxorubicin—ovarian cancer	0.000631	0.000817	CcSEcCtD
Cabergoline—Hyperhidrosis—Epirubicin—ovarian cancer	0.000623	0.000807	CcSEcCtD
Cabergoline—Arthralgia—Doxorubicin—ovarian cancer	0.000622	0.000806	CcSEcCtD
Cabergoline—Anxiety—Doxorubicin—ovarian cancer	0.00062	0.000803	CcSEcCtD
Cabergoline—Discomfort—Doxorubicin—ovarian cancer	0.000615	0.000796	CcSEcCtD
Cabergoline—Anorexia—Epirubicin—ovarian cancer	0.000615	0.000796	CcSEcCtD
Cabergoline—Dry mouth—Doxorubicin—ovarian cancer	0.000609	0.000788	CcSEcCtD
Cabergoline—Vomiting—Docetaxel—ovarian cancer	0.000608	0.000787	CcSEcCtD
Cabergoline—Rash—Docetaxel—ovarian cancer	0.000603	0.000781	CcSEcCtD
Cabergoline—Hypotension—Epirubicin—ovarian cancer	0.000603	0.00078	CcSEcCtD
Cabergoline—Dermatitis—Docetaxel—ovarian cancer	0.000602	0.00078	CcSEcCtD
Cabergoline—Confusional state—Doxorubicin—ovarian cancer	0.000602	0.000779	CcSEcCtD
Cabergoline—Headache—Docetaxel—ovarian cancer	0.000599	0.000775	CcSEcCtD
Cabergoline—Oedema—Doxorubicin—ovarian cancer	0.000597	0.000773	CcSEcCtD
Cabergoline—Musculoskeletal discomfort—Epirubicin—ovarian cancer	0.000587	0.000761	CcSEcCtD
Cabergoline—Shock—Doxorubicin—ovarian cancer	0.000587	0.00076	CcSEcCtD
Cabergoline—Insomnia—Epirubicin—ovarian cancer	0.000583	0.000755	CcSEcCtD
Cabergoline—Paraesthesia—Epirubicin—ovarian cancer	0.000579	0.00075	CcSEcCtD
Cabergoline—Hyperhidrosis—Doxorubicin—ovarian cancer	0.000577	0.000747	CcSEcCtD
Cabergoline—Dyspnoea—Epirubicin—ovarian cancer	0.000575	0.000744	CcSEcCtD
Cabergoline—Somnolence—Epirubicin—ovarian cancer	0.000573	0.000742	CcSEcCtD
Cabergoline—Anorexia—Doxorubicin—ovarian cancer	0.000569	0.000736	CcSEcCtD
Cabergoline—Nausea—Docetaxel—ovarian cancer	0.000568	0.000735	CcSEcCtD
Cabergoline—Dyspepsia—Epirubicin—ovarian cancer	0.000568	0.000735	CcSEcCtD
Cabergoline—Decreased appetite—Epirubicin—ovarian cancer	0.000561	0.000726	CcSEcCtD
Cabergoline—Hypotension—Doxorubicin—ovarian cancer	0.000558	0.000722	CcSEcCtD
Cabergoline—Fatigue—Epirubicin—ovarian cancer	0.000556	0.00072	CcSEcCtD
Cabergoline—Constipation—Epirubicin—ovarian cancer	0.000551	0.000714	CcSEcCtD
Cabergoline—Pain—Epirubicin—ovarian cancer	0.000551	0.000714	CcSEcCtD
Cabergoline—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	0.000544	0.000704	CcSEcCtD
Cabergoline—Insomnia—Doxorubicin—ovarian cancer	0.00054	0.000699	CcSEcCtD
Cabergoline—Paraesthesia—Doxorubicin—ovarian cancer	0.000536	0.000694	CcSEcCtD
Cabergoline—Dyspnoea—Doxorubicin—ovarian cancer	0.000532	0.000689	CcSEcCtD
Cabergoline—Feeling abnormal—Epirubicin—ovarian cancer	0.000531	0.000688	CcSEcCtD
Cabergoline—Somnolence—Doxorubicin—ovarian cancer	0.00053	0.000687	CcSEcCtD
Cabergoline—Gastrointestinal pain—Epirubicin—ovarian cancer	0.000527	0.000683	CcSEcCtD
Cabergoline—Dyspepsia—Doxorubicin—ovarian cancer	0.000525	0.00068	CcSEcCtD
Cabergoline—Decreased appetite—Doxorubicin—ovarian cancer	0.000519	0.000672	CcSEcCtD
Cabergoline—Fatigue—Doxorubicin—ovarian cancer	0.000514	0.000666	CcSEcCtD
Cabergoline—Pain—Doxorubicin—ovarian cancer	0.00051	0.000661	CcSEcCtD
Cabergoline—Constipation—Doxorubicin—ovarian cancer	0.00051	0.000661	CcSEcCtD
Cabergoline—Abdominal pain—Epirubicin—ovarian cancer	0.00051	0.00066	CcSEcCtD
Cabergoline—Feeling abnormal—Doxorubicin—ovarian cancer	0.000492	0.000637	CcSEcCtD
Cabergoline—Gastrointestinal pain—Doxorubicin—ovarian cancer	0.000488	0.000632	CcSEcCtD
Cabergoline—Hypersensitivity—Epirubicin—ovarian cancer	0.000475	0.000615	CcSEcCtD
Cabergoline—Abdominal pain—Doxorubicin—ovarian cancer	0.000472	0.000611	CcSEcCtD
Cabergoline—Asthenia—Epirubicin—ovarian cancer	0.000463	0.000599	CcSEcCtD
Cabergoline—Pruritus—Epirubicin—ovarian cancer	0.000456	0.000591	CcSEcCtD
Cabergoline—Diarrhoea—Epirubicin—ovarian cancer	0.000441	0.000571	CcSEcCtD
Cabergoline—Hypersensitivity—Doxorubicin—ovarian cancer	0.00044	0.000569	CcSEcCtD
Cabergoline—Asthenia—Doxorubicin—ovarian cancer	0.000428	0.000554	CcSEcCtD
Cabergoline—Dizziness—Epirubicin—ovarian cancer	0.000426	0.000552	CcSEcCtD
Cabergoline—Pruritus—Doxorubicin—ovarian cancer	0.000422	0.000547	CcSEcCtD
Cabergoline—Vomiting—Epirubicin—ovarian cancer	0.00041	0.000531	CcSEcCtD
Cabergoline—Diarrhoea—Doxorubicin—ovarian cancer	0.000408	0.000529	CcSEcCtD
Cabergoline—Rash—Epirubicin—ovarian cancer	0.000407	0.000526	CcSEcCtD
Cabergoline—Dermatitis—Epirubicin—ovarian cancer	0.000406	0.000526	CcSEcCtD
Cabergoline—Headache—Epirubicin—ovarian cancer	0.000404	0.000523	CcSEcCtD
Cabergoline—Dizziness—Doxorubicin—ovarian cancer	0.000395	0.000511	CcSEcCtD
Cabergoline—Nausea—Epirubicin—ovarian cancer	0.000383	0.000496	CcSEcCtD
Cabergoline—Vomiting—Doxorubicin—ovarian cancer	0.000379	0.000491	CcSEcCtD
Cabergoline—Rash—Doxorubicin—ovarian cancer	0.000376	0.000487	CcSEcCtD
Cabergoline—Dermatitis—Doxorubicin—ovarian cancer	0.000376	0.000487	CcSEcCtD
Cabergoline—Headache—Doxorubicin—ovarian cancer	0.000374	0.000484	CcSEcCtD
Cabergoline—Nausea—Doxorubicin—ovarian cancer	0.000354	0.000459	CcSEcCtD
Cabergoline—DRD2—GPCR downstream signaling—AKT1—ovarian cancer	7.24e-06	0.000132	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—CXCL8—ovarian cancer	7.22e-06	0.000132	CbGpPWpGaD
Cabergoline—ADRA2A—Metabolism—PTEN—ovarian cancer	7.21e-06	0.000132	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling by GPCR—PIK3CA—ovarian cancer	7.2e-06	0.000132	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—CDKN1B—ovarian cancer	7.2e-06	0.000132	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—VEGFA—ovarian cancer	7.18e-06	0.000131	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—STAT3—ovarian cancer	7.18e-06	0.000131	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling by GPCR—HRAS—ovarian cancer	7.17e-06	0.000131	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—CASP3—ovarian cancer	7.17e-06	0.000131	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—IL2—ovarian cancer	7.16e-06	0.000131	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—MAPK1—ovarian cancer	7.16e-06	0.000131	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—MAPK1—ovarian cancer	7.16e-06	0.000131	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—NRAS—ovarian cancer	7.16e-06	0.000131	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—EGFR—ovarian cancer	7.16e-06	0.000131	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—EGFR—ovarian cancer	7.16e-06	0.000131	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling by GPCR—AKT1—ovarian cancer	7.13e-06	0.00013	CbGpPWpGaD
Cabergoline—DRD2—Signaling by GPCR—IL6—ovarian cancer	7.12e-06	0.00013	CbGpPWpGaD
Cabergoline—HTR2A—GPCR downstream signaling—AKT1—ovarian cancer	7.12e-06	0.00013	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—STAT3—ovarian cancer	7.11e-06	0.00013	CbGpPWpGaD
Cabergoline—HTR1B—Signaling Pathways—PIK3CA—ovarian cancer	7.11e-06	0.00013	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—NRAS—ovarian cancer	7.09e-06	0.00013	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—VEGFA—ovarian cancer	7.09e-06	0.00013	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—ERBB2—ovarian cancer	7.07e-06	0.000129	CbGpPWpGaD
Cabergoline—HTR7—Signaling Pathways—TP53—ovarian cancer	7.07e-06	0.000129	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—CASP3—ovarian cancer	7.06e-06	0.000129	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—CDKN1B—ovarian cancer	7.05e-06	0.000129	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—IL2—ovarian cancer	7.05e-06	0.000129	CbGpPWpGaD
Cabergoline—HTR1D—Signaling Pathways—TP53—ovarian cancer	7.02e-06	0.000128	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—STAT3—ovarian cancer	7.02e-06	0.000128	CbGpPWpGaD
Cabergoline—HTR2A—Signaling by GPCR—IL6—ovarian cancer	7.01e-06	0.000128	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—NRAS—ovarian cancer	7e-06	0.000128	CbGpPWpGaD
Cabergoline—DRD4—Signaling Pathways—PIK3CA—ovarian cancer	6.99e-06	0.000128	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—CCND1—ovarian cancer	6.98e-06	0.000128	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—MTOR—ovarian cancer	6.98e-06	0.000128	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—PIK3CB—ovarian cancer	6.98e-06	0.000128	CbGpPWpGaD
Cabergoline—ADRA1A—GPCR downstream signaling—AKT1—ovarian cancer	6.97e-06	0.000127	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	6.93e-06	0.000127	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—VEGFA—ovarian cancer	6.93e-06	0.000127	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—CTNNB1—ovarian cancer	6.91e-06	0.000126	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—CASP3—ovarian cancer	6.91e-06	0.000126	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—IL2—ovarian cancer	6.9e-06	0.000126	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—VEGFA—ovarian cancer	6.9e-06	0.000126	CbGpPWpGaD
Cabergoline—HTR1B—Signaling Pathways—TP53—ovarian cancer	6.87e-06	0.000126	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—CCND1—ovarian cancer	6.87e-06	0.000126	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling by GPCR—IL6—ovarian cancer	6.86e-06	0.000125	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—STAT3—ovarian cancer	6.86e-06	0.000125	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—MAPK3—ovarian cancer	6.85e-06	0.000125	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—KRAS—ovarian cancer	6.85e-06	0.000125	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—NRAS—ovarian cancer	6.85e-06	0.000125	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—STAT3—ovarian cancer	6.83e-06	0.000125	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—NRAS—ovarian cancer	6.81e-06	0.000124	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—CTNNB1—ovarian cancer	6.8e-06	0.000124	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—MAPK3—ovarian cancer	6.79e-06	0.000124	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—MMP9—ovarian cancer	6.78e-06	0.000124	CbGpPWpGaD
Cabergoline—DRD4—Signaling Pathways—TP53—ovarian cancer	6.77e-06	0.000124	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—KRAS—ovarian cancer	6.76e-06	0.000124	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—KRAS—ovarian cancer	6.76e-06	0.000124	CbGpPWpGaD
Cabergoline—HTR7—Signaling Pathways—HRAS—ovarian cancer	6.76e-06	0.000124	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—PTEN—ovarian cancer	6.74e-06	0.000123	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—CCND1—ovarian cancer	6.73e-06	0.000123	CbGpPWpGaD
Cabergoline—HTR1D—Signaling Pathways—HRAS—ovarian cancer	6.71e-06	0.000123	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—CXCL8—ovarian cancer	6.71e-06	0.000123	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—VEGFA—ovarian cancer	6.71e-06	0.000123	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—MAPK3—ovarian cancer	6.71e-06	0.000123	CbGpPWpGaD
Cabergoline—HTR2B—Signaling Pathways—PIK3CA—ovarian cancer	6.68e-06	0.000122	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—MMP9—ovarian cancer	6.67e-06	0.000122	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—MYC—ovarian cancer	6.67e-06	0.000122	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling by GPCR—HRAS—ovarian cancer	6.66e-06	0.000122	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—CTNNB1—ovarian cancer	6.66e-06	0.000122	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—STAT3—ovarian cancer	6.64e-06	0.000121	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—PTEN—ovarian cancer	6.63e-06	0.000121	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—NRAS—ovarian cancer	6.62e-06	0.000121	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—MYC—ovarian cancer	6.61e-06	0.000121	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—VEGFA—ovarian cancer	6.6e-06	0.000121	CbGpPWpGaD
Cabergoline—HTR1B—Signaling Pathways—HRAS—ovarian cancer	6.57e-06	0.00012	CbGpPWpGaD
Cabergoline—DRD2—Signaling by GPCR—AKT1—ovarian cancer	6.57e-06	0.00012	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—MAPK3—ovarian cancer	6.56e-06	0.00012	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—CDKN1B—ovarian cancer	6.55e-06	0.00012	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—STAT3—ovarian cancer	6.54e-06	0.000119	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—MMP9—ovarian cancer	6.53e-06	0.000119	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—MAPK3—ovarian cancer	6.52e-06	0.000119	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—MAPK1—ovarian cancer	6.52e-06	0.000119	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—MYC—ovarian cancer	6.52e-06	0.000119	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—EGFR—ovarian cancer	6.52e-06	0.000119	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—NRAS—ovarian cancer	6.52e-06	0.000119	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—PTEN—ovarian cancer	6.49e-06	0.000119	CbGpPWpGaD
Cabergoline—ADRA2A—GPCR downstream signaling—AKT1—ovarian cancer	6.48e-06	0.000118	CbGpPWpGaD
Cabergoline—DRD4—Signaling Pathways—HRAS—ovarian cancer	6.47e-06	0.000118	CbGpPWpGaD
Cabergoline—HTR7—Signaling Pathways—IL6—ovarian cancer	6.47e-06	0.000118	CbGpPWpGaD
Cabergoline—HTR2A—Signaling by GPCR—AKT1—ovarian cancer	6.47e-06	0.000118	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—MAPK1—ovarian cancer	6.46e-06	0.000118	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—EGFR—ovarian cancer	6.46e-06	0.000118	CbGpPWpGaD
Cabergoline—HTR2B—Signaling Pathways—TP53—ovarian cancer	6.46e-06	0.000118	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—ABCB1—ovarian cancer	6.44e-06	0.000118	CbGpPWpGaD
Cabergoline—HTR1D—Signaling Pathways—IL6—ovarian cancer	6.43e-06	0.000117	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—CASP3—ovarian cancer	6.42e-06	0.000117	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—IL2—ovarian cancer	6.41e-06	0.000117	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—MAPK1—ovarian cancer	6.38e-06	0.000117	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—EGFR—ovarian cancer	6.38e-06	0.000117	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling by GPCR—IL6—ovarian cancer	6.38e-06	0.000117	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—MYC—ovarian cancer	6.38e-06	0.000117	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—MAPK3—ovarian cancer	6.34e-06	0.000116	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—MYC—ovarian cancer	6.34e-06	0.000116	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling by GPCR—AKT1—ovarian cancer	6.33e-06	0.000116	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—TYMS—ovarian cancer	6.32e-06	0.000116	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—PIK3CA—ovarian cancer	6.3e-06	0.000115	CbGpPWpGaD
Cabergoline—HTR1B—Signaling Pathways—IL6—ovarian cancer	6.29e-06	0.000115	CbGpPWpGaD
Cabergoline—ADRA2C—Metabolism—PIK3CA—ovarian cancer	6.26e-06	0.000114	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—CCND1—ovarian cancer	6.25e-06	0.000114	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—MAPK3—ovarian cancer	6.24e-06	0.000114	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—MAPK1—ovarian cancer	6.24e-06	0.000114	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—EGFR—ovarian cancer	6.24e-06	0.000114	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—PIK3CA—ovarian cancer	6.21e-06	0.000114	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—PIK3CA—ovarian cancer	6.21e-06	0.000114	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—MAPK1—ovarian cancer	6.21e-06	0.000113	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—EGFR—ovarian cancer	6.21e-06	0.000113	CbGpPWpGaD
Cabergoline—DRD4—Signaling Pathways—IL6—ovarian cancer	6.19e-06	0.000113	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—CTNNB1—ovarian cancer	6.19e-06	0.000113	CbGpPWpGaD
Cabergoline—HTR2B—Signaling Pathways—HRAS—ovarian cancer	6.18e-06	0.000113	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—MYC—ovarian cancer	6.17e-06	0.000113	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—KRAS—ovarian cancer	6.16e-06	0.000113	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—KRAS—ovarian cancer	6.1e-06	0.000112	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—TP53—ovarian cancer	6.09e-06	0.000111	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—VEGFA—ovarian cancer	6.09e-06	0.000111	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—MYC—ovarian cancer	6.07e-06	0.000111	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—MMP9—ovarian cancer	6.07e-06	0.000111	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—MAPK1—ovarian cancer	6.04e-06	0.00011	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—EGFR—ovarian cancer	6.04e-06	0.00011	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—PTEN—ovarian cancer	6.03e-06	0.00011	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—KRAS—ovarian cancer	6.03e-06	0.00011	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—STAT3—ovarian cancer	6.03e-06	0.00011	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—NRAS—ovarian cancer	6.01e-06	0.00011	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—TP53—ovarian cancer	6.01e-06	0.00011	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—TP53—ovarian cancer	6.01e-06	0.00011	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—VEGFA—ovarian cancer	5.99e-06	0.000109	CbGpPWpGaD
Cabergoline—HTR7—Signaling Pathways—AKT1—ovarian cancer	5.97e-06	0.000109	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—MAPK1—ovarian cancer	5.94e-06	0.000109	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—EGFR—ovarian cancer	5.94e-06	0.000109	CbGpPWpGaD
Cabergoline—HTR1D—Signaling Pathways—AKT1—ovarian cancer	5.93e-06	0.000108	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—STAT3—ovarian cancer	5.93e-06	0.000108	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—NRAS—ovarian cancer	5.91e-06	0.000108	CbGpPWpGaD
Cabergoline—HTR2B—Signaling Pathways—IL6—ovarian cancer	5.91e-06	0.000108	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—KRAS—ovarian cancer	5.89e-06	0.000108	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling by GPCR—AKT1—ovarian cancer	5.88e-06	0.000108	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—VEGFA—ovarian cancer	5.86e-06	0.000107	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—KRAS—ovarian cancer	5.86e-06	0.000107	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—HRAS—ovarian cancer	5.82e-06	0.000106	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—STAT3—ovarian cancer	5.81e-06	0.000106	CbGpPWpGaD
Cabergoline—HTR1B—Signaling Pathways—AKT1—ovarian cancer	5.81e-06	0.000106	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—NRAS—ovarian cancer	5.79e-06	0.000106	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—MAPK3—ovarian cancer	5.76e-06	0.000105	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—HRAS—ovarian cancer	5.75e-06	0.000105	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—HRAS—ovarian cancer	5.75e-06	0.000105	CbGpPWpGaD
Cabergoline—DRD4—Signaling Pathways—AKT1—ovarian cancer	5.71e-06	0.000104	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—KRAS—ovarian cancer	5.7e-06	0.000104	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—MAPK3—ovarian cancer	5.66e-06	0.000104	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—PIK3CA—ovarian cancer	5.66e-06	0.000103	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—KRAS—ovarian cancer	5.61e-06	0.000103	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—PIK3CA—ovarian cancer	5.61e-06	0.000102	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—MYC—ovarian cancer	5.6e-06	0.000102	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—IL6—ovarian cancer	5.57e-06	0.000102	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—MAPK3—ovarian cancer	5.55e-06	0.000101	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—PIK3CA—ovarian cancer	5.54e-06	0.000101	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—MYC—ovarian cancer	5.51e-06	0.000101	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—IL6—ovarian cancer	5.5e-06	0.000101	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—IL6—ovarian cancer	5.5e-06	0.000101	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—MAPK1—ovarian cancer	5.48e-06	0.0001	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—EGFR—ovarian cancer	5.48e-06	0.0001	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—TP53—ovarian cancer	5.48e-06	0.0001	CbGpPWpGaD
Cabergoline—HTR2B—Signaling Pathways—AKT1—ovarian cancer	5.45e-06	9.97e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—VEGFA—ovarian cancer	5.45e-06	9.96e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—TP53—ovarian cancer	5.43e-06	9.91e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—PIK3CA—ovarian cancer	5.41e-06	9.89e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—MYC—ovarian cancer	5.39e-06	9.86e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—STAT3—ovarian cancer	5.39e-06	9.86e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—MAPK1—ovarian cancer	5.39e-06	9.85e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—EGFR—ovarian cancer	5.39e-06	9.85e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—PIK3CA—ovarian cancer	5.39e-06	9.84e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—NRAS—ovarian cancer	5.38e-06	9.83e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—TP53—ovarian cancer	5.36e-06	9.79e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—MAPK1—ovarian cancer	5.28e-06	9.64e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—EGFR—ovarian cancer	5.28e-06	9.64e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—PIK3CA—ovarian cancer	5.24e-06	9.57e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—TP53—ovarian cancer	5.24e-06	9.57e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—HRAS—ovarian cancer	5.24e-06	9.57e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—TP53—ovarian cancer	5.21e-06	9.52e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—HRAS—ovarian cancer	5.19e-06	9.48e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—KRAS—ovarian cancer	5.17e-06	9.45e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—PIK3CA—ovarian cancer	5.16e-06	9.42e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—MAPK3—ovarian cancer	5.15e-06	9.42e-05	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—AKT1—ovarian cancer	5.14e-06	9.4e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—HRAS—ovarian cancer	5.12e-06	9.36e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Metabolism—AKT1—ovarian cancer	5.12e-06	9.35e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—CAV1—ovarian cancer	5.1e-06	9.31e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—KRAS—ovarian cancer	5.09e-06	9.3e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Metabolism—PIK3CA—ovarian cancer	5.09e-06	9.3e-05	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—AKT1—ovarian cancer	5.07e-06	9.27e-05	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—AKT1—ovarian cancer	5.07e-06	9.27e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—TP53—ovarian cancer	5.07e-06	9.26e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—MYC—ovarian cancer	5.01e-06	9.16e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—IL6—ovarian cancer	5.01e-06	9.16e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—HRAS—ovarian cancer	5.01e-06	9.15e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—TP53—ovarian cancer	4.99e-06	9.11e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—KRAS—ovarian cancer	4.98e-06	9.11e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—HRAS—ovarian cancer	4.98e-06	9.11e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—IL6—ovarian cancer	4.97e-06	9.07e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—MAPK1—ovarian cancer	4.9e-06	8.96e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—IL6—ovarian cancer	4.9e-06	8.96e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—EGFR—ovarian cancer	4.9e-06	8.96e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—HRAS—ovarian cancer	4.85e-06	8.86e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—IL6—ovarian cancer	4.79e-06	8.76e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—HRAS—ovarian cancer	4.77e-06	8.72e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—IL6—ovarian cancer	4.77e-06	8.72e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—PIK3CA—ovarian cancer	4.75e-06	8.69e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—PIK3CA—ovarian cancer	4.68e-06	8.55e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—PIK3CG—ovarian cancer	4.64e-06	8.48e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—IL6—ovarian cancer	4.64e-06	8.48e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—KRAS—ovarian cancer	4.63e-06	8.46e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—AKT1—ovarian cancer	4.62e-06	8.45e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—TP53—ovarian cancer	4.6e-06	8.4e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—AKT1—ovarian cancer	4.58e-06	8.37e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—PIK3CA—ovarian cancer	4.58e-06	8.37e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—IL6—ovarian cancer	4.57e-06	8.34e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—TP53—ovarian cancer	4.52e-06	8.27e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—AKT1—ovarian cancer	4.52e-06	8.26e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—TP53—ovarian cancer	4.43e-06	8.1e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—AKT1—ovarian cancer	4.42e-06	8.08e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—AKT1—ovarian cancer	4.4e-06	8.04e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—HRAS—ovarian cancer	4.4e-06	8.04e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—HRAS—ovarian cancer	4.33e-06	7.91e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—AKT1—ovarian cancer	4.28e-06	7.82e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—PIK3CA—ovarian cancer	4.25e-06	7.78e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—HRAS—ovarian cancer	4.24e-06	7.74e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—AKT1—ovarian cancer	4.21e-06	7.7e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—IL6—ovarian cancer	4.21e-06	7.69e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Metabolism—AKT1—ovarian cancer	4.16e-06	7.6e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—IL6—ovarian cancer	4.14e-06	7.57e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—TP53—ovarian cancer	4.12e-06	7.52e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—PIK3CD—ovarian cancer	4.08e-06	7.46e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—IL6—ovarian cancer	4.06e-06	7.41e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—HRAS—ovarian cancer	3.94e-06	7.19e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—AKT1—ovarian cancer	3.88e-06	7.1e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—AKT1—ovarian cancer	3.82e-06	6.98e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—IL6—ovarian cancer	3.77e-06	6.89e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—AKT1—ovarian cancer	3.74e-06	6.84e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—PIK3CB—ovarian cancer	3.56e-06	6.5e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—AKT1—ovarian cancer	3.48e-06	6.35e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—PTEN—ovarian cancer	3.07e-06	5.62e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—PIK3CA—ovarian cancer	2.17e-06	3.96e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—AKT1—ovarian cancer	1.77e-06	3.24e-05	CbGpPWpGaD
